Antibody Drug Therapy

Conventional anticancer therapeutics often suffers from lack of specificity, resulting in toxicities to normal healthy tissues and poor therapeutic index. Antibody-drug conjugates (ADCs) constitute a therapeutic modality in which a cytotoxic agent is chemically linked to an antibody (Ab) that recognizes a tumor-associated antigen. The basic strategy underlying ADC technology is to combine the target selectivity of mAbs with the potency of cytotoxic agents, such as certain natural products and synthetic molecules, with the goal of generating therapeutic drugs that are highly efficacious but also safe. The ADC platform currently includes a growing repertoire of cytotoxic payloads, linker technologies and conjugation methods. Two ADCs have recently received FDA approval and more than 30 are in clinical development. This meeting aims to highlight advances in ADC research, clinical development and regulatory perspectives.

  • Innovative Antibody drugs in clinical trail and development
  • Antibody-drug conjugate (ADC) discovery and development
  • Bispecific and multispecific antibody discovery and development
  • Challenges and new opportunities with antibody and protein drugs
  • Novel antibody and biologic drug targets

Related Conference of Antibody Drug Therapy

September 24-26, 2018

14th International Conference on Structural Biology

Berlin, Germany
October 03-04, 2018 |

4th International Conference on Biochemistry & Metabolomics

Los Angeles, California, USA
October 18-19, 2018

10th International Congress on Structural Biology

Helsinki, Finland
November 19-20, 2018

15th World Congress on

Structural Biology

Paris, France
February 28-March 01, 2019

5th International Conference on Enzymology and Protein Chemistry

Berlin, Germany
July 31-August 01, 2019

6th International Conference on Glycobiology & Glycoproteomics

Chicago, Illinois, USA

Antibody Drug Therapy Conference Speakers

Recommended Sessions

Related Journals

Are you interested in